Almirall, the medical dermatology company based in Barcelona, Spain, reported €889.2 million in sales for the first nine months of 2026, up 8.3% from a year earlier, as its European skin-disease business and newer biologic medicines continued to grow.
In its November 9 earnings announcement, the company maintained its full-year forecast for sales growth of 9% to 12% and earnings before interest, taxes, depreciation and amortization of €270 million to €290 million. The figures cover January through September, rather than the third quarter alone.
Almirall reported nine-month EBITDA of €221.7 million, up 22.7%, with an EBITDA margin of 24.9%, compared with 22.0% a year earlier. Reported net income rose to €53.3 million from €39.1 million. EBITDA is a measure of operating earnings before several costs; the smaller net-income figure is a separate measure, not an interchangeable profit total.
European dermatology sales increased 17.6% to €520.3 million. That growth was faster than the group’s overall increase, making the division the main driver of the results. Total company revenue, which includes other income, was €893.6 million, distinct from the €889.2 million net-sales figure.
The strongest named growth driver was Ebglyss, or lebrikizumab, used for moderate-to-severe atopic dermatitis. Its sales rose 75.0% to €132.1 million. Ilumetri, or tildrakizumab, used for moderate-to-severe plaque psoriasis, generated €190.6 million, up 11.5%. These are commercial sales results; they do not by themselves establish how either medicine compares with another treatment for an individual patient.
The broader portfolio also contributed. Sales of the psoriasis treatment Wynzora increased 15.4% to €29.3 million, while Klisyri, used for actinic keratosis, rose 18.4% to €23.8 million. The results show that Almirall’s growth is not confined to a single product, even as the company emphasizes its biologic medicines.
For investors, the significance is the combination of higher sales and a faster increase in operating earnings, while the company leaves its annual forecast unchanged. The nine-month results are evidence of the business’s performance to September, not a guarantee that the remaining quarter will deliver the forecast.
Almirall said research and development spending represented about 12% of net sales. Four proof-of-concept or Phase II studies are under way, with two further proof-of-concept studies planned toward year-end. The programmes target several skin diseases and include work on a rare inflammatory disease, pyoderma gangrenosum. Early-stage studies test whether a treatment approach warrants further development; they are not approvals or confirmed future products.
The company expects its first pipeline readouts this quarter, but the announcement does not report those results. It also does not provide a product-by-product forecast for the final quarter. Whether the research succeeds and how strongly the commercial portfolio finishes the year remain open questions. Almirall lists February 22, 2027, for its full-year financial results.
JBizNews Desk | Barcelona, Spain
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
